Calidi Biotherapeutics (NYSE:CLDI – Get Free Report) and Immatics (NASDAQ:IMTX – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.
Earnings and Valuation
This table compares Calidi Biotherapeutics and Immatics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Calidi Biotherapeutics | $50,000.00 | 355.72 | -$29.22 million | N/A | N/A |
| Immatics | $115.50 million | 7.08 | -$104.98 million | ($0.66) | -10.38 |
Calidi Biotherapeutics has higher earnings, but lower revenue than Immatics.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Calidi Biotherapeutics | 0 | 0 | 3 | 0 | 3.00 |
| Immatics | 0 | 0 | 4 | 1 | 3.20 |
Calidi Biotherapeutics currently has a consensus target price of $16.67, suggesting a potential upside of 1,125.49%. Immatics has a consensus target price of $16.67, suggesting a potential upside of 143.31%. Given Calidi Biotherapeutics’ higher probable upside, research analysts plainly believe Calidi Biotherapeutics is more favorable than Immatics.
Volatility & Risk
Calidi Biotherapeutics has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500. Comparatively, Immatics has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500.
Insider and Institutional Ownership
12.5% of Calidi Biotherapeutics shares are owned by institutional investors. Comparatively, 64.4% of Immatics shares are owned by institutional investors. 24.3% of Calidi Biotherapeutics shares are owned by insiders. Comparatively, 3.3% of Immatics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Calidi Biotherapeutics and Immatics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Calidi Biotherapeutics | N/A | N/A | -344.45% |
| Immatics | -47.94% | -15.90% | -9.38% |
Summary
Calidi Biotherapeutics beats Immatics on 7 of the 13 factors compared between the two stocks.
About Calidi Biotherapeutics
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.
About Immatics
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
Receive News & Ratings for Calidi Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calidi Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
